The earnings call discussed progress in Ovaprene study enrollment and upcoming milestones. Interim review expected by end of Q2 2025 will focus on safety in open-label study. Operational progress for Sildenafil Cream phase three involves defining endpoints and aligning with FDA on efficacy and safety expectations.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing